ChromaDex names Jeffrey Himmel CEO

Tuesday, January 24, 2012 08:39 AM

ChromaDex, based in Irvine, Calif., has named Jeffrey Himmel its new CEO. Previous CEO Frank Jaksch will assume the position of chief scientific officer and remain on the ChromaDex board of directors.

Himmel also has agreed to invest $1 million in ChromaDex.

Himmel previously has held positions at Rothschild and Jeffrey Martin, an over-the-counter pharmaceutical company founded by his father, Martin Himmel. He also is the former chairman of The Himmel Group and currently serves as a member of the board of directors of The Consumer Healthcare Products Association.

Share:          
CWWeekly

February 21

Survey: Sponsors, CROs making changes to their business models to demonstrate value to payers

Cegedim ranks top pharma companies on their use of, and success with, social media

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

February

Anticipating the rise of virtual drug development
With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have...

Closing investigative site operations a complex process
In light of the shrinking investigative site landscape, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into...

Eye On Shire
Shire is a rapidly growing, global specialty biopharmaceutical company, directly marketing its products in over 50 countries...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs